Thirty-one patients with advanced gastric cancer were entered into the trial between May 1988 to June 1993. The patient received 5-fluorouracil 1,000mg/m* by 12-hour continuous infusions for 5 consecutive days, cisplatin 100mg/m* Ⅳ on day 1 and
repeated every three weeks.
@ES The results were as following;
@EN 1) Among the 31 treated patients, 27 patients had measurable disease and were evaluable for response. The overall response rate was 18.5%. The median duration of response was 6 months.
2) The estimated median survival time was 7.5 months for all 31 patients. the median survival was 8.6 months in responder, and 6.4 months in non-responder. There was no significant difference between the two group.
3) Nausea and vomiting of WHO grades 2 and 3 were observed in 48.7%. Alopecia was observed in all patients, but most of patients were WHO grade 1 or 2. WHO grades 1 and 2 neurotoxicities and diarrhea occurred in 22.6%, 7.8% of patients. WHO
grades
2 and
3 neutropenia were observed in 2.6% of patients and WHO grade 1 thrombocytopenia was observed in 9.6% of patients, but there were no toxic deaths and no bleeding complication from thrombocytopenia.
In conclusion, although this FP regimen showed similar toxicity profiles than the other regimen, response rate and survival benefit were not observed.
|